// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

PARTICIPANTS' EXPERIENCE OF THE MAKING IT WORK PROGRAM, AN ONLINE PROGRAM TO HELP PEOPLE WITH INFLAMMATORY ARTHRITIS REMAIN EMPLOYED

A. Li - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

PATTERNS OF ETANERCEPT DOSE ADJUSTMENTS IN A REAL–WORLD SETTING: A CANADIAN RETROSPECTIVE COHORT STUDY

M. Khraishi - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Etanercept

PREGNANCY AND PARENTING WITH ARTHRITIS – DEVELOPING AN EDUCATIONAL RESOURCE FOR PATIENT BY PATIENTS

L. Proulx - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

PRISM – PICTORIAL REPRESENTATION OF ILLNESS AND SELF MEASURE: THE USE OF A SIMPLE NON-VERBAL TOOL AS A PATIENT-CENTRED OUTCOME MEASURE IN EARLY RHEUMATOID ARTHRITIS COHORTS

P.C. Taylor - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

N/A

RETENTION RATES OF TNF INHIBITORS AND ABATACEPT USED AS A FIRST BIOLOGIC DMARD IN THE TREATMENT OF RHEUMATOID ARTHRITIS: 8 YEARS OF EXPERIENCE FROM THE RHUMADATA® REGISTRY

D. Choquette - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Certolizumab pegol

RITUXIMAB SHOWS BETTER SUSTAINABILITY THAN TNF INHIBITORS WHEN USED FOLLOWING INITIAL BIOLOGIC DMARD FAILURE IN THE TREATMENT OF RHEUMATOID ARTHRITIS: 8 YEARS OF REAL-WORLD OBSERVATIONS FROM THE RHUMADATA® CLINICAL DATABASE AND REGISTRY

D. Choquette - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Rituximab

SUBCHONDRAL BONE SCLEROSIS ON COMPUTED TOMOGRAPHY – DOES IT HAVE ANY VALUE IN THE DIAGNOSIS OF INFLAMMATORY SACROILIITIS OR IS IT A NON-SPECIFIC FINDING?

O. Azmat - European League Against Rheumatism (EULAR) , 2017

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

N/A

N/A

Physiatrist-Led Pain Outreach Clinic in Primary Care

David Ruggles - American Academy of Pain Medicine (AAPM) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Update on regulation of steroidogenesis by aberrant hormone receptors

Andre Lacroix - European Congress of Endocrinology (ECE) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Inducible thyrocyte-specific Gs alpha-deficient mice as a novel model for hypothyroidism

Konrad Patyra - European Congress of Endocrinology (ECE) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Tamoxifen

Type 1 diabetes and hearing loss: a meta-analysis

Mario Mujica-Mota - European Congress of Endocrinology (ECE) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

The method of reporting hypoglycemia in Randomized Control Trials (RCTs): a systematic review on RCTs conducted for SGLT-2 inhibitors

Noor Kassir - European Congress of Endocrinology (ECE) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Outcome of patients with adrenocortical cancer after discontinuation of adjuvant mitotane therapy

Massimo Terzolo - European Congress of Endocrinology (ECE) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Lysodren

Evaluating CHARGE syndrome in CHD7-positive CHH patients: clinical implications

Cheng Xu - European Congress of Endocrinology (ECE) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

N/A

Chronic hypoparathyroidism disease profile from 492 patients in the PARADIGHM™ natural history global registry

Bart L Clarke - European Congress of Endocrinology (ECE) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Hydrochlorothiazide

A modelling approach for cost-savings in the elderly ontarian population with type 2 diabetes due to reduction in mild hypoglycemia events for SGLT-2 inhibitor versus sulfonylurea (SU) initiation after metformin

Pendar Farahani - European Congress of Endocrinology (ECE) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

sulfonylureas

Hypoglycemia, weight changes and health related quality of life (HRQoL) instruments for diabetes care

Carolyn Akladious - European Congress of Endocrinology (ECE) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Decreased HDL cholesterol efflux capacity in morbidly obese individuals as a surrogate marker for increased cardiovascular risk

Idit Dotan - European Congress of Endocrinology (ECE) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Genetic variants of the adiponectin gene and its association with adiponectin level in metabolic syndrome women

Abhishek Gupta - European Congress of Endocrinology (ECE) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Resveratrol increases hepatic SHBG expression through human constitutive androstane receptor: a new Contribution to the French Paradox

Cristina Saez-Lopez - European Congress of Endocrinology (ECE) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

Resveratrol

Copyright © 2026. QuantiNova All rights reserved